Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corp
(NQ:
INCY
)
67.24
-0.25 (-0.37%)
Streaming Delayed Price
Updated: 9:50 AM EDT, Oct 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'
March 24, 2023
Via
Benzinga
Incyte Stock Dives On Surprise Rejection For Updated Jakafi
March 24, 2023
The company had hoped to gain approval for an extended-release version of its biggest drug.
Via
Investor's Business Daily
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
March 23, 2023
From
Incyte
Via
Business Wire
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
March 23, 2023
Via
Benzinga
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
March 22, 2023
From
Incyte
Via
Business Wire
Analyst Expectations for Incyte's Future
March 07, 2023
Via
Benzinga
Incyte's Return On Capital Employed Overview
February 08, 2023
Via
Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
March 21, 2023
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.
Via
InvestorPlace
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
March 18, 2023
From
Incyte Corporation
Via
Business Wire
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
March 18, 2023
From
Incyte Corporation
Via
Business Wire
Analyst Ratings for Incyte
February 08, 2023
Via
Benzinga
Earnings Outlook For Incyte
February 06, 2023
Via
Benzinga
2 Steady Stocks to Buy in a Recession
February 03, 2023
Both companies are performing better than the broader market over the past year.
Via
The Motley Fool
Why Shares of MacroGenics Climbed Thursday
March 16, 2023
The cancer-focused biotech delivered a strong earnings report.
Via
The Motley Fool
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
March 14, 2023
From
Incyte Corporation
Via
Business Wire
Which S&P 500 Stocks Look Most Attractive Now?
March 08, 2023
Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH.
Via
Talk Markets
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
March 06, 2023
From
Incyte
Via
Business Wire
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns
March 06, 2023
Via
Benzinga
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
March 03, 2023
From
Incyte
Via
Business Wire
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
February 24, 2023
From
Incyte Corporation
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
February 16, 2023
From
Incyte
Via
Business Wire
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
February 10, 2023
From
Incyte
Via
Business Wire
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
February 07, 2023
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled.
Via
Investor's Business Daily
Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst
February 07, 2023
Via
Benzinga
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
February 07, 2023
From
Incyte
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
January 31, 2023
Via
Benzinga
Incyte to Present at Upcoming Investor Conference
January 24, 2023
From
Incyte
Via
Business Wire
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
January 19, 2023
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.
Via
Investor's Business Daily
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Via
InvestorPlace
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers
January 18, 2023
From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.